OncoBioTek Overview
- Founded
-
2009
- Status
-
Out of Business
- Employees
-
1
- Latest Deal Type
-
Out of Business
OncoBioTek General Information
Description
Developer of veterinary drugs designed to offer support to treat and cure canine cancer. The company's drug is made by using a comparative oncology approach to identify and validate human cancer drugs that have significant potential for the treatment of cancer in the dog, enabling physicians to ensure efficient treatment and faster recovery of dogs suffering from cancer.
Contact Information
Primary Industry
Biotechnology
Other Industries
Drug Discovery
Primary Office
- 138 Allee Des Lucioles
- Chateauneuf Villevieille
- 06390 Nice
- France
+33 06 00 00 00 00
OncoBioTek Valuation & Funding
| Deal Type | Date | Amount | Raised to Date | Post-Val | Status | Stage |
|---|---|---|---|---|---|---|
| 3. Out of Business | 01-Sep-2018 | Completed | Out of Business | |||
| 2. Equity Crowdfunding | 01-Mar-2017 | Cancelled | Generating Revenue/Not Profitable | |||
| 1. Early Stage VC | Completed | Generating Revenue/Not Profitable |
OncoBioTek Patents
OncoBioTek Recent Patent Activity
| Publication ID | Patent Title | Status | First Filing Date | Technology (CPC) | Citations |
|---|---|---|---|---|---|
| EP-2456854-B1 | Method for obtaining myofibroblasts | Inactive | 24-Jul-2009 | 0000000000 | |
| EP-2456854-A1 | Method for obtaining myofibroblasts | Active | 24-Jul-2009 | 0000000000 | |
| ES-2650664-T3 | Procedure for obtaining myofibroblasts | Active | 24-Jul-2009 | 0000000000 | |
| FR-2948381-B1 | Process for obtaining myofibroblasts | Active | 24-Jul-2009 | 0000000000 | |
| FR-2948381-A1 | Process for obtaining myofibroblasts | Active | 24-Jul-2009 | C12N5/0656 | 0 |
OncoBioTek Executive Team (3)
| Name | Title | Board Seat | Contact Info |
|---|---|---|---|
| Tony Dutton | Chief Executive Officer & Board Member | ||
| Robert Barthel Ph.D | Founder, Board Member and Chief Scientific Officer |
OncoBioTek Board Members (5)
| Name | Representing | Role | Since |
|---|---|---|---|
| Berndt Modig | Self | Board Member | 000 0000 |
| Michele Garufi | Self | Board Member | 000 0000 |
| Robert Barthel Ph.D | OncoBioTek | Founder, Board Member and Chief Scientific Officer | 000 0000 |
| Tony Dutton | OncoBioTek | Chief Executive Officer & Board Member | 000 0000 |
| Zsolt Lavotha | Self | Chairman | 000 0000 |
OncoBioTek Signals
Growth Rate
0.80%
Weekly
Growth
Growth
Weekly Growth
0.80%, 93rd %
-35.5%.
530%
Size Multiple
219x
Median
Size Multiple
219x, 100th %ile
0.00x
0.95x.
413Kx
Key Data Points
Twitter Followers
5.5k
Similarweb Unique Visitors
15.0K
Majestic Referring Domains
314
